 |
|
| Blog results | Results 1 - 10 of about 2,610 for new + invega + schizophrenia. (0.20 seconds) |
| Sorted by relevance Sort by date |
| 19 Nov 2009 by DrugsNews New data from a 6-month open label randomised controlled trial show INVEGA® (paliperidone ER) is associated with significantly less metabolic effects compared to oral olanzapine in people with schizophrenia, while demonstrating ... Drugs Reviews | Dugs News - http://www.drugs-review.com/ |
| 16 Nov 2009 Johnson & Johnson is looking at innovative ways to build the value of its just-approved, monthly injectable schizophrenia drug Invega Sustenna, including continuing ongoing outcomes studies and creating appropriate partnerships with ... "The Pink Sheet" :: PRESCRIPTION... - http://thepinksheet.elsevierbi.com/cs/Satellite?c... |
| 3 Aug 2009 INVEGA(R) SUSTENNA(TM) is the First Once-Monthly Atypical Antipsychotic Approved for Schizophrenia in the US. ... economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. ... Latest articles from PMD - http://www.pmdcentral.com/ |
| 2 Aug 2009 by Mark Ellis Said Nasrallah: “Inconsistent compliance with medications is arguably one of the single greatest impediments to managing the symptoms of schizophrenia and delaying the time to relapse. The approval of once-monthly INVEGA SUSTENNA will ... Bizzia - http://www.bizzia.com/ |
| 19 Nov 2009 by Management Software Content 'Minimising treatment-related metabolic effects is an important clinical goal for effective management of schizophrenia, and this study demonstrates that INVEGA can help meet this need.' The study. Management Software Review - http://managementsoftwarereview.org/ |
| 20 Nov 2009 August 03, 2009. The FDA has approved Invega Sustenna (paliperidone palmitate, from Janssen) extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults. .... New Drug Products ... Latest articles from MPR - http://www.empr.com/ - References [ More results from Latest articles from MPR ] |
| 17 Nov 2009 by Sean ... monthly injectable schizophrenia drug Invega Sustenna for free or at a huge discount to payers if specified outcomes are not achieved, as part of a broader plan for a "new treatment paradigm" in the treatment of schizophrenia. BioPharma Today - http://www.biopharmatoday.com/ |
| 6 hours ago by AdPharm For acute and maintenance treatment of schizophrenia. Rethink the way you treat. New Once-Monthly Invega Sustenna. Brand name: Invega Sustenna Generic name/category: paliperidone palmitate, atypical antipsychotic. Company: Janssen ... AdPharm Blog - http://blog.adpharm.net/ |
| 6 Aug 2009 by Psych Central News Editor Invega Antipsychotic Approved for Schizophrenia, Schizoaffective Disorder Last week, the U.S. Food and Drug Administration (FDA) handed down two new approvals for Invega (paliperidone), an atypical antipsychotic medication, ... Psych Central News - http://psychcentral.com/news/ - References [ More results from Psych Central News ] |
| 2 Aug 2009 Invega Approved By FDA as New Treatment for Schizophrenia - December 21, 2006. Janssen, L.P. Selects Invega (paliperidone) Extended Release Tablets as Brand Name for Its Investigational Atypical Antipsychotic - November 10, 2006 ... Drugs.com - New Drug Approvals - http://www.drugs.com/newdrugs.html - References [ More results from Drugs.com - New Drug Approvals ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
